Clinical-stage immunooncology company Imugene (ASX:IMU) has announced new data from its Phase 1b clinical trial evaluating azercabtagene zapreleucel in patients with relapsed or refractory diffuse large B-cell lymphoma …
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
July 14, 2025 Australian Biotech
Latest Video
New Stories
-
Olympian joins call urging vigilance on meningococcal risk
July 15, 2025 - - Latest News -
HTA reform is fine, but why is the underpinning framework immutable?
July 15, 2025 - - Latest News -
Patient Voice Initiative announces the appointment of new president
July 15, 2025 - - Latest News -
Amplia Therapeutics announces additional confirmed partial response in ACCENT trial
July 14, 2025 - - Australian Biotech -
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
July 14, 2025 - - Australian Biotech -
Is Australia in a position to lecture any country about affordable access to medicines?
July 14, 2025 - - Latest News -
Biotintelect amongst groups funded to foster research commercialisation
July 13, 2025 - - Australian Biotech